Biotech News

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Nurix Therapeutics (NRIX)Nurix Therapeutics2026-06-25 13:46 ESTClinical readout

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the

Open original release

Related news

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics to Participate in Upcoming Investor Conferences

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

NRIXNurix Therapeutics2026-06-25 13:46 EST

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

View all latest news

Nurix Therapeutics

Nurix Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

NRIXZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

NRIXZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

NRIXBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

NRIXGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

NRIXMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 22.71 USD
Market cap: 2.39B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States